Nuvectis Pharma, Inc.

FORT LEE, NJ · Founded 2020 · CIK 0001875558 · Biotech · Public

NXP900, an oral small molecule inhibitor of SRC Family Kinases with dual catalytic and scaffolding function inhibition

nuvectis.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$16M
1 Form D · Aug 2022
50 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$15,878,637
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2525Sonata Biosciences Inc——
2526GENTEL BIOSCIENCES INC—$2.7M
2527Insilico Medicine, Inc.—$20M
2528Nuvectis Pharma, Inc.—$16M
2529ImmuneBridge Inc.—$16M
2530IpiNovyx Bio, Inc.—$7.0M
2531Lang Artificial Intelligence, Inc.—$11M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Ron BentsurDirector · Executive Officer
  • Michael CarsonExecutive Officer
  • Kenneth HobermanDirector
  • Matthew KaplanDirector
  • James OlivieroDirector
  • Enrique PoradosuExecutive Officer
  • Shay ShemeshExecutive Officer

Patents

USPTO · 0 granted of 10
  • Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
  • Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
  • Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication
  • Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
  • Crystalline Forms Of A Tyrosine Kinase Inhibitorapplication
  • Tyrosine Kinase Inhibitorsapplication
  • Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication
  • Crystalline Forms Of The Tyrosine Kinase Inhibitor ECF506application
  • Crystalline Salt Forms Of The Tyrosine Kinase Inhibitor ECF506application
  • Methods Of Treating Cancer Using HSF1 Pathway Inhibitorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.